drugset / Trial / NCT00843778
Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study
NaSingle-groupOpen-labelTreatment
Summary
To continue to assess the clinical safety and efficacy of Certolizumab Pegol as add-on therapy with stable-dose Disease Modifying Anti-Rheumatic Drugs (DMARDs)
Timeline
- Start
- 2009-01
- Primary completion
- 2012-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Certolizumab Pegol | Protein / enzyme biologic | 200 mg | — |